Gilde Healthcare has raised €250M for its 4th fund in an oversubscribed round. The money will go to late-stage MedTech, digital health and therapeutics, which can join a portfolio with some of the European celebrity-Biotechs.
Gilde Healthcare is based in Utrecht (Netherlands) and Cambridge (Massachussets), investing in healthcare companies on both sides of the Atlantic.
This VC has now raised €250M for its 4th fund – Gilde Healthcare IV. The round was backed by a mix of international investors, which included well-known Dutch company Philips (technology giant also with MedTech products) and Johnson & Johnson Innovation (US).
For the IV Fund, single investments in each biotech will be between €15M and €25M. The current portfolio includes companies like Agendia (which developed a diagnostic test for breast cancer), Acacia (developing anti-nausea medication) and Symphogen (one of the top biotechs in Copenhagen).
Gilde’s strategy to investing focuses on later stages of Biotech, MedTech and Digital Health companies (such as Series C rounds). Some of the big names in Gilde’s exits wall of fame are Ablynx, Evotec, UniQure and Galapagos.
Even with its late-stage strategy (less risk, but also less potential for growth in portfolio companies), a quarter of a billion euros is still very impressive. It beats other 2016 rounds for investment funds, like the €210M launch of Medicxi Ventures in February, the €180M fundraising by Forbion in April and the €204M fundraising by MVM Capital in May.
This is yet another example of how VC financing is strong in biotech. Which biotechs could now become part of Gilde’s portfolio?
Feature Image Credit: Pixabay